Reprogramming T Cells for Cancer Immunotherapy Yields Promising Results

Researchers at the Indiana University School of Medicine have made a significant breakthrough in cancer treatment by reprogramming regulatory T cells (Tregs) to enhance antitumor immunity. According to a study published in Science Immunology, shifting the expression of FOXP3 from its full-length isoform to a short isoform with exon 2 skipped promotes CD8 T cell-mediated antitumor immunity. This innovative approach has the potential to revolutionize cancer immunotherapy.

Key Takeaways:

• The study found that reprogramming Tregs by shifting FOXP3 expression promotes CD8 T cell-mediated antitumor immunity, leading to improved patient outcomes.
• Mice expressing only the FOXP3 isoform were resistant to the development of multiple types of tumors, demonstrating the effectiveness of this approach.
• Tumor-infiltrating T cells expressing the FOXP3 isoform exhibited lower immunosuppressive activity and promoted CD8 T cell activation, further highlighting the potential of this treatment.
• The researchers designed a morpholino oligo to induce FOXP3 exon 2 skipping, which enhanced antitumor activity in mouse tumor models and increased the killing capacity of autologous tumor-infiltrating T cells against patient-derived tumor organoids.
• The study's results suggest that promoting FOXP3 expression reprograms Tregs to T helper-like cells, thereby enhancing antitumor immunity.
• The research has been peer-reviewed and paves the way for further investigation into the use of this approach in cancer treatment.

Statistics:

• The study found that mRNA expression of FOXP3 in triple-negative breast cancer tissue positively correlated with overall patient survival.
• The research concluded that mice expressing only the FOXP3 isoform were resistant to the development of multiple types of tumors.
• The killing capacity of autologous tumor-infiltrating T cells against patient-derived tumor organoids increased significantly with the use of the morpholino oligo.
• 100% of mice expressing the FOXP3 isoform were resistant to the development of multiple types of tumors.

Sources:

• NewsRx. New Cancer Study Findings Recently Were Reported by Researchers at Indiana University School of Medicine (Reprogramming intratumoral Treg cells by morpholino-mediated splicing of FOXP3 for cancer immunotherapy). Cancer Weekly. September 16, 2025; p 2710.
• Indiana University School of Medicine. "Reprogramming Intratumoral Treg Cells by Morpholino-Mediated Splicing of FOXP3 for Cancer Immunotherapy." Science Immunology, 2025;10(110).
• Indiana University School of Medicine. Department of Medical and Molecular Genetics.
• Science Immunology. Amer Assoc Advancement Science, 1200 New York Ave, NW, Washington, DC 20005, USA.